163 related articles for article (PubMed ID: 28576673)
1. Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.
Weber M; Niespodziana K; Linhart B; Neubauer A; Huber H; Henning R; Valenta R; Focke-Tejkl M
J Allergy Clin Immunol; 2017 Nov; 140(5):1433-1436.e6. PubMed ID: 28576673
[No Abstract] [Full Text] [Related]
2. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Focke-Tejkl M; Weber M; Niespodziana K; Neubauer A; Huber H; Henning R; Stegfellner G; Maderegger B; Hauer M; Stolz F; Niederberger V; Marth K; Eckl-Dorna J; Weiss R; Thalhamer J; Blatt K; Valent P; Valenta R
J Allergy Clin Immunol; 2015 May; 135(5):1207-7.e1-11. PubMed ID: 25441634
[TBL] [Abstract][Full Text] [Related]
5. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG
Eckl-Dorna J; Weber M; Stanek V; Linhart B; Ristl R; Waltl EE; Villazala-Merino S; Hummel A; Focke-Tejkl M; Froeschel R; Neubauer A; Henning R; Perkmann T; Valenta R; Niederberger V
EBioMedicine; 2019 Dec; 50():421-432. PubMed ID: 31786130
[TBL] [Abstract][Full Text] [Related]
6. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination.
Focke M; Mahler V; Ball T; Sperr WR; Majlesi Y; Valent P; Kraft D; Valenta R
FASEB J; 2001 Sep; 15(11):2042-4. PubMed ID: 11511525
[TBL] [Abstract][Full Text] [Related]
7. A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help.
Narayanan M; Freidl R; Focke-Tejkl M; Baranyi U; Wekerle T; Valenta R; Linhart B
J Immunol; 2017 Feb; 198(4):1685-1695. PubMed ID: 28093528
[TBL] [Abstract][Full Text] [Related]
8. Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy.
Linhart B; Focke-Tejkl M; Weber M; Narayanan M; Neubauer A; Mayrhofer H; Blatt K; Lupinek C; Valent P; Valenta R
J Immunol; 2015 Apr; 194(8):4008-18. PubMed ID: 25786690
[TBL] [Abstract][Full Text] [Related]
9. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity.
Linhart B; Jahn-Schmid B; Verdino P; Keller W; Ebner C; Kraft D; Valenta R
FASEB J; 2002 Aug; 16(10):1301-3. PubMed ID: 12154002
[TBL] [Abstract][Full Text] [Related]
10. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
Rask C; Lund L; Lund G; Heydenreich B; Wurtzen P; Bellinghausen I; Saloga J; Lund K
Clin Exp Allergy; 2012 Sep; 42(9):1356-68. PubMed ID: 22925322
[TBL] [Abstract][Full Text] [Related]
11. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination.
Linhart B; Hartl A; Jahn-Schmid B; Verdino P; Keller W; Krauth MT; Valent P; Horak F; Wiedermann U; Thalhamer J; Ebner C; Kraft D; Valenta R
J Allergy Clin Immunol; 2005 May; 115(5):1010-6. PubMed ID: 15867859
[TBL] [Abstract][Full Text] [Related]
12. Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells.
Rauber MM; Möbs C; Campana R; Henning R; Schulze-Dasbeck M; Greene B; Focke-Tejkl M; Weber M; Valenta R; Pfützner W
Allergy; 2020 Feb; 75(2):450-453. PubMed ID: 31330050
[No Abstract] [Full Text] [Related]
13. Discontinuous IgE-binding epitopes contain multiple continuous epitope regions: results of an epitope mapping on recombinant Hol l 5, a major allergen from velvet grass pollen.
Schramm G; Bufe A; Petersen A; Haas H; Merget R; Schlaak M; Becker WM
Clin Exp Allergy; 2001 Feb; 31(2):331-41. PubMed ID: 11251635
[TBL] [Abstract][Full Text] [Related]
14. Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein.
Mothes-Luksch N; Stumvoll S; Linhart B; Focke M; Krauth MT; Hauswirth A; Valent P; Verdino P; Pavkov T; Keller W; Grote M; Valenta R
J Immunol; 2008 Oct; 181(7):4864-73. PubMed ID: 18802090
[TBL] [Abstract][Full Text] [Related]
15. Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32.
Tulaeva I; Cornelius C; Zieglmayer P; Zieglmayer R; Schmutz R; Lemell P; Weber M; Focke-Tejkl M; Karaulov A; Henning R; Valenta R
EBioMedicine; 2020 Sep; 59():102953. PubMed ID: 32855110
[TBL] [Abstract][Full Text] [Related]
16. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
[TBL] [Abstract][Full Text] [Related]
17. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
[TBL] [Abstract][Full Text] [Related]
18. Design and evaluation of a hypoallergenic peptide-based vaccine for Salsola kali allergy.
Tabesh S; Fanuel S; Fazlollahi MR; Yekaninejad MS; Kardar GA; Razavi SA
Int Immunopharmacol; 2019 Jan; 66():62-68. PubMed ID: 30445308
[TBL] [Abstract][Full Text] [Related]
19. In Silico Design of a New Epitope-Based Vaccine against Grass Group 1 Allergens.
Moten D; Batsalova T; Apostolova D; Mladenova T; Dzhambazov B; Teneva I
Adv Respir Med; 2023 Nov; 91(6):486-503. PubMed ID: 37987298
[TBL] [Abstract][Full Text] [Related]
20. Nisin-induced expression of recombinant T cell epitopes of major Japanese cedar pollen allergens in Lactococcus lactis.
Van Hoang V; Ochi T; Kurata K; Arita Y; Ogasahara Y; Enomoto K
Appl Microbiol Biotechnol; 2018 Jan; 102(1):261-268. PubMed ID: 29094185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
